Navigation Links
Verenium to Present at Jefferies 10th Global Clean Technology Conference
Date:11/9/2010

CAMBRIDGE, Mass., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced that Janet Roemer, President and Chief Operating Officer, will present at the upcoming Jefferies 10th Global Clean Technology Conference.  The presentation is scheduled to begin at 3:45 p.m. GMT on Tuesday, November 16, 2010 and will take place in London.

More information about this event, including a live webcast, may be accessed by visiting the "Investors" section of Verenium's website at www.verenium.com.  A webcast replay will be available approximately one hour after the live webcasts end and will be accessible for one month following these conferences.  

About Verenium

Verenium Corporation is a pioneer in the development and commercialization of high-performance enzymes for use in industrial processes.  Verenium currently sells enzymes developed using its R&D capabilities to industrial customers globally for use in markets including grain and oilseed processing, biofuels, animal health and nutrition and other specialty industrial processes. Verenium has built a world-class R&D organization renowned for its capabilities in the rapid screening, identification, evolution and bioengineering of novel enzymes that act as catalysts for biochemical reactions. The company harnesses the power of nature and uses its unique, patented technology to create products that transform industries by maximizing efficiency while improving environmental performance. For more information on Verenium, visit http://www.verenium.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2009 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Kelly Lindenboom

Vice President, Corporate Communications

617-674-5335

kelly.lindenboom@verenium.com


Sarah Carmody

Manager, Corporate Communications

617-674-5357

sarah.carmody@verenium.com





'/>"/>
SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
2. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
3. Verenium Corporation to Announce Third Quarter 2008 Financial Results
4. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
5. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
6. Verenium Announces First Commercial Cellulosic Ethanol Project
7. Verenium Announces Organizational Changes
8. Verenium Completes Amendment to 8% Senior Convertible Notes
9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
10. Verenium Announces Reverse Stock Split to Take Effect September 9
11. Verenium 1:12 Reverse Stock Split Takes Effect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... The American Academy of Thermology ... offering its 2016 AAT Member Certification Qualification Course for Technicians via a two part ... which will include a detailed review of hardware, software, and camera setup/operations, aligns with ...
(Date:2/9/2016)... Feb. 9, 2016 This market research report ... and future prospects of the market in terms of ... companies engaged in the manufacture of microbiology culture media ... with a market snapshot providing the overall information of ... report. This section also provides the overall information and ...
(Date:2/9/2016)... Feb. 9, 2016 ... 2016", report provides in depth insights on ... around the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. ... in various stages of development including Discovery, ... III and Preregistration. Report covers the product ...
(Date:2/8/2016)... --> ... oncology company developing next generation cancer therapeutics that ... that chairman emeritus of Tata Sons Limited, Mr ... as part of the first close of Invictus,s ... Capital and Aarin Capital. http://photos.prnewswire.com/prnh/20150923/766442 ) ...
Breaking Biology Technology:
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first day ... announced plans to develop a first of its kind ... of IBM Watson. In the first application of ... (NYSE: IBM ), and Welltok will create a ... assessments with cognitive analytics, delivered on Welltok,s health optimization ...
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
(Date:1/25/2016)... BLUE BELL, Pa. , Jan. 25, 2016   Unisys ... facial recognition system at John F. Kennedy (JFK) International Airport, ... and Border Protection (CBP) identify imposters attempting to enter ... or do not belong to them. pilot testing ... rolled out initially at three terminals at JFK during January 2016. ...
Breaking Biology News(10 mins):